[ad_1]
In a statement made by the British Ministry of Health, it was stated that a group of researchers from the universities of Oxford, Sheffield, Liverpool, Newcastle and Birmingham examined the immune response that occurred after the vaccine in health workers who received the vaccine. first dose of Pfizer. -BioNTech Kovid-19 vaccine.
In the statement, it was noted that T cell and antibody responses were analyzed in blood samples taken from 257 healthcare workers who received the first dose of the vaccine between December 9, 2020 and February 9, 2021.
In the statement, which reported that 99 percent of those who received the first dose of the vaccine had a strong immune response, it was stated that the vaccine also provided protection against severe disease caused by Kovid 19.
In the statement, it was reported that the research results support the view that the second dose of Pfizer-BionTech’s Kovid-19 vaccine, which provides high protection with the first dose, can be done after a long time, and that by prioritizing the first dose, more people in the risk group can be protected.
The T-cell and antibody response in people who received a dose of vaccine after Kovid-19 was stated to be greater than in those who received a dose of vaccine without Covid-19, and it was stated that the T-cell response and antibodies that were produced after the vaccine was not yet known.
British Health Minister Matt Hancock, whose assessments were included in the statement, said the study revealed further evidence that vaccines provide “excellent” protection against the virus.
Hancock noted that thanks to his “successful” vaccination program, more than 50 percent of adults in the country are vaccinated and his goal is to offer vaccines to all adults by July.
[ad_2]
